Bioventus Inc.
For the period ended Sep 26, 2026. Filed Nov 2, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 26, 2026 · Filed Nov 2, 2026
BVS$11.18+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Condensed Statements of Cash Flows for the
Consolidated Condensed Statements of Cash Flows
Nine Months Ended September 26, 2026 and September 27, 2025
(Amounts in thousands)
| Nine Months Ended | ||
|---|---|---|
| September 26, 2026 | September 27, 2025 | |
| Operating activities: | ||
| Net income | $47,010 | $9,956 |
| Adjustments to reconcile net income to net cash from operating activities: | ||
| Depreciation and amortization | 32,465 | 35,317 |
| Provision for credit losses | 189 | 944 |
| Equity-based compensation | 13,061 | 9,233 |
| Deferred income taxes | (22,641) | 222 |
| Loss on disposals | — | 81 |
| Loss on extinguishment | — | 326 |
| Unrealized loss (gain) on foreign currency fluctuations | 151 | (333) |
| Other, net | 508 | 1,006 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (10,471) | (2,801) |
| Inventories | (3,215) | (4,399) |
| Accounts payable and accrued expenses | (7,453) | (15,370) |
| Other current and noncurrent assets and liabilities | (139) | 2,523 |
| Net cash from operating activities | 49,465 | 36,705 |
| Investing activities: | ||
| Settlement from the sale of a business | — | (686) |
| Purchase of property and equipment | (1,868) | (1,982) |
| Acquisition of distribution rights | (1,500) | — |
| Purchase of equity securities | (1,500) | — |
| Net cash from investing activities | (4,868) | (2,668) |
| Financing activities: | ||
| Proceeds from issuance of Class A common stock | 2,388 | 1,563 |
| Tax withholdings on equity-based compensation | (1,357) | (9) |
| Payment of contingent consideration | — | (19,771) |
| Borrowing on revolver | — | 45,000 |
| Payment on revolver | — | (20,000) |
| Proceeds from the issuance of long-term debt, net of discount | — | 31,907 |
| Payments on the extinguishment of long-term debt | — | (65,765) |
| Debt refinancing costs | — | (697) |
| Payments on long-term debt | (64,500) | (5,302) |
| Other, net | (690) | (619) |
| Net cash from financing activities | (64,159) | (33,693) |
| Effect of exchange rate changes on cash | (967) | 238 |
| Net change in cash and cash equivalents | (20,529) | 582 |
| Cash and cash equivalents at the beginning of the period | 51,238 | 41,582 |
| Cash and cash equivalents at the end of the period | $30,709 | $42,164 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Accounts payable for purchase of property, plant and equipment | $285 | $218 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.